-+ 0.00%
-+ 0.00%
-+ 0.00%

Zymeworks Q2 FY26 net loss widens to $45 million; revenue guidance rises to $278 million-$292 million for FY26

PUBT·09/28/2026 10:00:39
Listen to the news
Zymeworks Q2 FY26 net loss widens to $45 million; revenue guidance rises to $278 million-$292 million for FY26
  • Zymeworks reported a GAAP net loss of USD 45 million for the quarter ended June 30, 2026, versus net income of USD 2.3 million a year earlier.
  • First-half 2026 GAAP net loss widened to USD 89.2 million from USD 20.3 million in the prior-year period.
  • Updated 2026 outlook calls for revenue of USD 278 million to USD 292 million following the Theravance Biopharma acquisition.
  • Theravance deal adds YUPELRI profit-share cash flows; first-half 2026 YUPELRI sales were USD 133.1 million, generating USD 38.4 million collaboration revenue.
  • Zymeworks expects 2026 adjusted EBITDA of USD 114 million to USD 128 million and plans to retain the existing commercial team supporting YUPELRI hospital promotion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zymeworks Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280600OMX_____CNEWS_EN_GNW9834648_en) on September 28, 2026, and is solely responsible for the information contained therein.